by Global Recombinant Plasma Protein Therapeutics Market – Snapshot
The global recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant therapies, rise in awareness about rare disease management and increased focus on investments in rare diseases. Additionally, steady increase in the number of patients with rare hematological diseases and product approvals by regulatory authorities such as the Food and Drug Administration (FDA), European Commission, and Ministry of Health, Labour and Welfare (Japan) are anticipated to drive the market significantly during the forecast period. However, the high cost of treatment and availability of alternative therapies are likely to restrain the global market.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111956
The global recombinant plasma protein therapeutics market has been segmented based on drug class, cell line, and indication. Based on drug class, the market has been classified into recombinant coagulation factors and human C1 esterase inhibitor. The recombinant coagulation factors segment has been further sub-segmented into recombinant coagulation factor VIII, recombinant coagulation factor IX, recombinant coagulation factor VIIa, and others. The recombinant coagulation factor VIII sub-segment is projected to account for a major share of the recombinant coagulation factors segment of the market by 2026, due to the increase in number of hemophilia A cases across the globe, new product launches, and use of recombinant plasma protein therapies for the treatment of hemophilia A. The recombinant coagulation factor VIIa sub-segment is anticipated to expand at a steady pace during the forecast period. In terms of cell line, the market has been categorized into Chinese hamster ovary (CHO) cell line, baby hamster kidney (BHK) cell line, human embryonic kidney (HEK) cell line, and others. The Chinese hamster ovary (CHO) cell line segment is expected to expand at a prominent CAGR due to an increase in the utilization of CHO cell lines for manufacturing therapeutic products. Based on indication, the market has been segregated into hemophilia A, hemophilia B, Von Willebrand disease, and others
Based on region, the global recombinant plasma protein therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to hold a prominent share of the global market. In North America, the market in the U.S. is anticipated to expand at a rapid pace, due to a surge in the demand for recombinant coagulation factor VII and IX, rise in the emphasis on the management of rare diseases such as hemophilia A, hemophilia B, and Von Willebrand disease, and increase in the number of market players offering recombinant plasma proteins. Additionally, market players are focused on increasing global presence through distribution agreements, partnerships, and geographical expansion.
In Europe, increasing number of established biotechnology & pharmaceutical companies and research institutes, universities, and commercial players are obtaining funds for research & development studies in the field of recombinant DNA technology, which in turn is projected to boost the market. Furthermore, advancements in genetic engineering and biotechnology in countries such as Germany, U.K., and France significantly drive the opportunities of developing new therapeutics products for diseases. Moreover, in January 2017, CSL Limited received approval and marketing authorization from European Commission for AFSTYLA, indicated for the treatment of Hemophilia A. Such approvals increased the availability of drugs in Europe.
Major players operating in the global recombinant plasma protein therapeutics market include CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk A/S, Bayer AG, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group NV, and Pfizer Inc.
Expanding Cases of Hemophilia among many Individuals to Bring Profitable Growth for the Recombinant Plasma Protein Therapeutics Market
The recombinant plasma protein therapeutics market will gain considerable growth opportunities during the forecast period of 2018-2026 owing to an increase in the demand for advanced therapies across a large chunk of the global populace. Technological advancements and an increase in research and development activities coupled with the rising geriatric population are some major factors that will influence the growth to a considerable extent.
Plasma proteins are prominently utilized in replacement therapies. These therapies are used for treating rare conditions such as hemophilia and other bleeding disorders. The expanding number of rare hematology cases will bring promising growth.
Diverse awareness campaigns organized by various government and non-government organizations about hemophilia A and hemophilia B will bring tremendous growth opportunities for the recombinant plasma protein therapeutics market Furthermore, quick approvals from regulatory authorities are also helping the recombinant plasma protein therapeutics market to gain good growth opportunities. These factors bode well for the growth.
Rising investment in research and development activities from the players in the recombinant plasma protein therapeutics market will serve as a vital growth-generating aspect. The players invest in these activities for formulating new developments and strategies that help in increasing the demand for recombinant plasma protein therapeutics. These activities eventually help in sowing the seeds of growth.
The players also indulge in strategic collaborations. The collaborations strengthen the position of manufacturers in the recombinant plasma protein therapeutics market, which ultimately results in an increase in the growth rate.
The COVID-19 pandemic will not have much impact on the growth of the recombinant plasma protein therapeutics market as it comes under healthcare services and is exempt from all sorts of lockdown restrictions. The lockdown restrictions imposed by numerous countries at the start of the pandemic in 2020 had a minimal negative effect on the recombinant plasma protein therapeutics market.
The global recombinant plasma protein therapeutics market has been segmented as below:
Drug Class
- Recombinant Coagulation Factors
- Recombinant Coagulation Factor VIII
- Recombinant Coagulation Factor IX
- Recombinant Coagulation Factor VIIa
- Others
- Human C1 Esterase Inhibitor
Cell Line
- Chinese Hamster Ovary (CHO) Cell Line
- Baby Hamster Kidney (BHK) Cell Line
- Human Embryonic Kidney (HEK) Cell Line
- Others
Indication
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- India
- China
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111956/2900
